news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

【Introduction】Changchun Hi-Tech's interim report is released, 9 directors, supervisors and senior executives plan to increase their holdings by a total of no less than 15 million yuan

China Fund News reporter Qiu Dekun

On the evening of August 15, Changchun High-Tech, the "first growth hormone stock", released its 2024 semi-annual report showing that the company achieved operating income of 6.639 billion yuan, a year-on-year increase of 7.63%; net profit attributable to shareholders was 1.720 billion yuan.

On the same evening, Changchun Hi-Tech announced that the company's chairman and general manager Jiang Yuntao and nine other directors, supervisors and senior managers plan to increase their holdings of the company's shares within six months from the date of disclosure of this announcement, with the total amount of increase not less than 15 million yuan.

Genetically engineered drugs industry is the main source of revenue

The company's official website shows that Changchun High-Tech was listed on the Shenzhen Stock Exchange on December 18, 1996, and has formed three major industry development platforms: genetic engineering drugs, biological vaccines, and modern Chinese medicine.

Source: Changchun Hi-Tech official website

in,The genetic engineering drug industry is the main source of Changchun High-Tech's operating incomeIn the first half of 2024, Changchun High-Tech's genetically engineered biological drugs achieved revenue of 5.771 billion yuan, accounting for 86.94% of its operating income.

Changchun High-Tech introduced that the company is one of the few companies in the world that has three generations of growth hormone products, namely powder injection, water injection and long-acting water injection. The growth hormone series of drugs currently have 12 approved indications and have maintained a leading position in the domestic market share.

The main implementing entity of Changchun High-Tech in the genetic engineering pharmaceutical industry is its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as Jinsai Pharmaceutical).

In the first half of 2024, Jinsai Pharmaceutical achieved revenue of 5.152 billion yuan, a year-on-year increase of 0.25%; net profit attributable to shareholders of the parent was 1.769 billion yuan, a year-on-year decrease of 19.49%.

9 directors, supervisors and senior executives plan to increase their holdings

On the evening of August 15, Changchun Hi-Tech also announced a plan for some directors, supervisors and senior managers to increase their holdings in the company's shares.

Changchun Hi-Tech announced that the company's chairman and general manager Jiang Yuntao and nine other directors, supervisors and senior managers plan to increase their holdings in the company's shares within six months from the date of disclosure of this announcement, with the total amount of increase not less than 15 million yuan.

Currently, the total number of directors, supervisors and senior managers of Changchun Hi-Tech is 16. The above 9 directors, supervisors and senior managers who intend to participate in the share purchase plan have exceeded half of the total number of directors, supervisors and senior managers.

At the same time, some of the above-mentioned directors, supervisors and senior managers who intend to participate in the share purchase plan, Jiang Yuntao, Zhu Xinggong, Ye Peng and Li Xiufeng, also serve as directors, supervisors and senior managers of Jinsai Pharmaceutical, a subsidiary of Changchun Hi-Tech.

Changchun High-Tech announced that some directors, supervisors and senior managers plan to increase their holdings in the company's shares based on their confidence in the company's future development and recognition of its long-term investment value, and out of rational judgment of the company's valuation and considerations of further boosting market confidence.

The above-mentioned share purchase plan shows that some directors, supervisors and senior managers plan to increase their holdings of Changchun High-Tech shares without setting a price range. The share purchase plan will be implemented at an appropriate time based on the fluctuations in Changchun High-Tech's stock price and the overall trend of the capital market.

The list of Changchun High-Tech's top ten shareholders shows that northbound funds increased their holdings of the company's shares by 1.9955 million shares in the first quarter of 2024, but reduced their holdings of the company's shares by 1.4655 million shares in the second quarter. As of June 30, the number of Changchun High-Tech's shareholders was 135,800.

As of August 15, Changchun High-Tech's share price was 89.39 yuan per share, with a total market value of 36.15 billion yuan.

Editor: Xiaomo

Review: Xu Wen

Copyright Notice

"China Fund News" enjoys the copyright to the original content published on this platform. Reproduction without authorization is prohibited, otherwise legal liability will be pursued.

Contact person for authorized reprint cooperation: Mr. Yu (Tel: 0755-82468670)